Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

autologous anti-ALPP CAR retroviral vector-transduced T cells

A preparation of autologous T lymphocytes that have been transduced with a retroviral vector expressing a chimeric antigen receptor (CAR) targeting alkaline phosphatase, placental type (ALPP; placental alkaline phosphatase; PLAP), with potential immunostimulating and antineoplastic activities. Upon infusion back into the patient, autologous anti-ALPP CAR retroviral vector-transduced T cells target and bind to ALPP-expressing tumor cells, thereby inducing selective toxicity in ALPP-expressing tumor cells. ALPP, mainly expressed in placenta and testis, is overexpressed on certain tumor cell types, such as on a proportion of colorectal cancers while not expressed in any other normal tissues. It plays a key role in tumor cell proliferation.
Synonym:anti-ALPP CAR-expressing retroviral vector-transduced autologous T cells
autologous anti-ALPP CAR T cells
autologous anti-ALPP CAR-modified T cells
retroviral vector-transduced anti-PLAP CAR autologous T cells
Search NCI's Drug Dictionary